Results 21 to 30 of about 5,551,009 (351)
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]
, 2019 Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence +2 more
core +2 more sources
Top 10 Challenges in Cancer Immunotherapy.
Immunity, 2020 Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a ...
P. Hegde, Daniel S. Chen
semanticscholar +1 more source
mRNA vaccine for cancer immunotherapy
Molecular Cancer, 2021 mRNA vaccines have become a promising platform for cancer immunotherapy. During vaccination, naked or vehicle loaded mRNA vaccines efficiently express tumor antigens in antigen-presenting cells (APCs), facilitate APC activation and innate/adaptive immune
Lei Miao, Yu Zhang, Leaf Huang
semanticscholar +1 more source
Lung Cancer Immunotherapy [PDF]
Clinical Medicine & Research, 2005 Recent insights into anti-tumor immunotherapy have led to a wave of clinical trials involving immunotherapy for lung cancer. Vaccines have evolved from nonspecific immune stimulants, like Bacillus Calmette-Guerin (BCG), to much more specific and potent strategies, some of which generate active immune responses against tumor-associated antigens ...
Luis E, Raez +2 more
openaire +2 more sources
Scientific Reports, 2021 Despite recent progress in therapeutic strategies, prognosis of metastatic triple-negative breast cancer (TNBC) remains dismal. Evidence suggests that the induction and activation of tumor-residing conventional type-1 dendritic cells (cDC1s) is critical ...
Toshihiro Yokoi +4 more
doaj +1 more source
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Journal of experimental & clinical cancer research : CR, 2022 Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made tremendous progress with five CAR T therapies approved by the US Food and Drug Administration for hematological malignancies.
K. Pan +5 more
semanticscholar +1 more source
Prostate Cancer Immunotherapy [PDF]
Clinical Cancer Research, 2011 AbstractThe interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent U.S. Food and Drug Administration approval of 2 first-in-class proof-of-concept immunotherapies (sipuleucel-T and ipilimumab) has stimulated broader interest in manipulating immunity to fight cancer. In the context
Kenneth F, May +4 more
openaire +2 more sources
ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism
OncoImmunology, 2017 Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components.
Alina Steinbach +9 more
doaj +1 more source
Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]
, 2016 Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios +4 more
core +3 more sources
CD8+ T cells regulate tumor ferroptosis during cancer immunotherapy
Nature, 2019 Cancer immunotherapy restores or enhances the effector function of CD8+ T cells in the tumour microenvironment1,2. CD8+ T cells activated by cancer immunotherapy clear tumours mainly by inducing cell death through perforin–granzyme and Fas–Fas ligand ...
Weimin Wang +29 more
semanticscholar +1 more source